Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Vaxart Inc. manages a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 2 pending office actions, both of which are being reviewed within 1 distinct art unit. This concentration suggests that the company's current filings are technically similar or closely related. The 2 pending office actions are assigned to 2 distinct examiners, providing the company with two different perspectives within the same technical group.
ALLEN, MICHAEL D is the busiest examiner for the company, overseeing 1 busiest examiner pending action. This indicates that the 2 pending office actions are split between the 2 distinct examiners. Managing 2 pending office actions within 1 distinct art unit allows for a focused prosecution strategy, though the company must still address the individual requirements of 2 distinct examiners. This structure highlights a specialized area of development for Vaxart Inc. in the Biotechnology & Pharmaceuticals sector. Practitioners should note that while the art unit is the same, the presence of 2 distinct examiners means that the company's patent outcomes are not dependent on a single individual's review. The 2 pending office actions represent the current active workload for the company's biotech intellectual property.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEN, MICHAEL D | 1 | 31.9% | +48.8% |
| SIFFORD, JEFFREY MARK | 1 | 55.1% | +32.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18263462 | CHIMERIC ADENOVIRAL VECTORS | ALLEN, MICHAEL D | 4d overdue |
| 18000638 | CHIMERIC ADENOVIRAL VECTORS | SIFFORD, JEFFREY MARK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18263462 | CHIMERIC ADENOVIRAL VECTORS | ALLEN, MICHAEL D | 4d overdue |
| 18000638 | CHIMERIC ADENOVIRAL VECTORS | SIFFORD, JEFFREY MARK | — |
| Art Unit | Apps |
|---|---|
| 1671 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18263462 | CHIMERIC ADENOVIRAL VECTORS | ALLEN, MICHAEL D | 1671 | §102§103§112Other | Non-Final OA | 4d overdue | Pending | Jul 28, 2023 |
| 18000638 | CHIMERIC ADENOVIRAL VECTORS | SIFFORD, JEFFREY MARK | 1671 | §103§112Other | Non-Final OA | — | Pending | Dec 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVaxart Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Michael D Allen has the most, with 1 of Vaxart Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
